Paper Details

  1. Home
  2. Paper Details

Efficacy, Tolerability, and Retention of Antiseizure Medications in <i>PRRT2</i>-Associated Infantile Epilepsy.

Author: BastThomas, BrockmannKnut, DöringJan H, EhrhardtLaura, FazeliWalid, HoffmannGeorg F, JanzarikWibke G, Klabunde-CherwonAnnick, KlugerGerhard, KölkerStefan, MuhleHiltrud, MøllerRikke S, PendziwiatManuela, PlatzerKonrad, SaffariAfshin, SantosJoana Larupa, SchröterJulian, SyrbeSteffen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the treatment response of antiseizure medications (ASMs) in children with monogenic PRRT2-associated infantile epilepsy.
Paper Details　
Original Abstract of the Article :
Label="Background and Objectives" NlmCategory="UNASSIGNED">Pathogenic variants in <i>PRRT2</i>, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520344/

データ提供：米国国立医学図書館（NLM）

PRRT2-Associated Infantile Epilepsy: Evaluating the Efficacy of Antiseizure Medications

This research examines the treatment response to antiseizure medications (ASMs) in children with PRRT2-associated infantile epilepsy. The authors investigated the efficacy, tolerability, and retention of ASMs in a specific group of patients with this genetic epilepsy syndrome. This research, like a beacon of hope in the desert of epilepsy treatment, aims to improve the management and care for children with this challenging condition.

Finding the Right Path for PRRT2 Epilepsy

This study provides valuable insights into the treatment response of ASMs in children with PRRT2-associated infantile epilepsy. By studying the efficacy, tolerability, and retention of different medications, the authors offer guidance for clinicians seeking to optimize treatment for these patients. This is like discovering a new trail through a desert landscape, finding a more effective and tailored approach to managing this specific form of epilepsy.

Guiding Treatment Decisions and Improving Patient Outcomes

The findings of this research can inform treatment decisions and improve patient outcomes for children with PRRT2-associated infantile epilepsy. By understanding the efficacy and tolerability of different ASMs, clinicians can select the most appropriate medications to manage seizures and minimize side effects. This is like having a compass to navigate the desert of epilepsy treatment, providing a more precise and effective approach to care.

Dr. Camel's Conclusion

This research is a testament to the ongoing effort to find better treatments for children with epilepsy. By investigating the efficacy and tolerability of ASMs in PRRT2-associated infantile epilepsy, the authors offer valuable insights to guide clinical practice and improve patient outcomes. The desert of epilepsy research is vast and complex, but with continued research and innovation, we can find more effective therapies and bring hope to children living with this challenging condition.
Date :
  1. Date Completed n.d.
  2. Date Revised 2022-10-04
Further Info :

Pubmed ID

36187725

DOI: Digital Object Identifier

PMC9520344

Related Literature

Article Analysis
・Side Effects of oxcarbazepine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.